Rhapontin activates nuclear factor erythroid 2-related factor 2 to ameliorate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced gastrointestinal dysfunction in Parkinson's disease mice

Figure 1 The network pharmacology analysis of rhapontin treatment of Parkinson's disease. A: The chemical structure of rhapontin; B: Venn diagram of overlapping targets associated with rhapontin in Parkinson's disease (PD); C: Protein-protein interaction of potential targets of rhapontin to treat PD. The deeper the color, the greater the degree. The line between two nodes represents the interaction; D: Gene ontology functional enrichment analysis. PD: Parkinson's disease; PPI: Protein-protein interaction; GO: Gene ontology; BP: Biological process; CC: Cell component; MF: Molecular function.